sellWeak
Benjamin L Palleiko sold $104k of KALV
CHIEF EXECUTIVE OFFICER at KalVista Pharmaceuticals, Inc.. 7,169 shares at an average of $14.50, traded Jun 9, 2025, filed Jun 10, 2025.
Warning score
20Value
$104k
7,169 shares
Holdings after
315,074
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +10Trade size$104k at market
- 0Share of holdings soldSold 2.2% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-016522, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 6, 2025 | MOption exercise Common Stock | +15,625 | - | - | 322,243 | Jun 10, 2025 |
| Jun 9, 2025 | SOpen-market sale Common Stock | -7,169 | $14.50 | $104k | 315,074 | Jun 10, 2025 |
| Jun 6, 2025 | MOption exercise Restricted Stock Unitderivative | -15,625 | $0.00 | $0 | 171,876 | Jun 10, 2025 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 7Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $60k 2,239 shares | -1% | |
| 8Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $72k 2,685 shares | -2% | |
| 5Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $28k 1,032 shares | -1% | |
| 7Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $54k 2,686 shares | -2% | |
| 37Weak | KALVsell KalVista Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. owner | $3.7M 214,631 shares | -4% | |
| 35Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $108k 6,693 shares | -1% | |
| 24Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $83k 5,354 shares | -4% | |
| 36Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $156k 10,034 shares | -2% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $68k 4,347 shares | -2% | |
| 32Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $28k 1,767 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.